Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance

References

• EpsteinFHFaderlSTalpazMThe biology of chronic myeloid leukemiaN Engl J Med1999341316417210403855
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCAntoliniLMahonF-XMulticenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinibJ Natl Cancer Inst2011103755356121422402
   PubMedGoogle Scholar
• BowerHBjorkholmMDickmanPWHoglundMLambertPCAnderssonTM-LLife expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general populationJ Clin Oncol201634242851285727325849
   PubMed Web of Science ®Google Scholar
• MoslehiJJDeiningerMTyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemiaJ Clin Oncol201533354210421826371140
   PubMed Web of Science ®Google Scholar
• KrauseDSVan EttenRATyrosine kinases as targets for cancer therapyN Engl J Med2005 353235317218716014887
   PubMed Web of Science ®Google Scholar
• BellingerAMArteagaCLForceTCardio-oncologyCirculation2015132232248225826644247
   PubMedGoogle Scholar
• D’AgostinoRBVasanRSPencinaMJGeneral cardiovascular risk profile for use in primary care: the Framingham heart studyCirculation2008117674375318212285
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet20043649438937952
   PubMed Web of Science ®Google Scholar
• KaptogeSDi AngelantonioEPennellsLC-reactive protein, fibrinogen, and cardiovascular disease predictionN Engl J Med2012367141310132023034020
   PubMed Web of Science ®Google Scholar
• KimTDReaDSchwarzMPeripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinibLeukemia20132761316132123459449
   PubMed Web of Science ®Google Scholar
• CortesJEKimD-WPinilla-IbarzJA phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemiasN Engl J Med2013369191783179624180494
   PubMed Web of Science ®Google Scholar
• LiWCroceKSteensmaDPMcDermottDFBen-YehudaOMoslehiJVascular and metabolic implications of novel targeted cancer therapiesJ Am Coll Cardiol201566101160117826337996
   PubMed Web of Science ®Google Scholar
• HochhausASaglioGHughesTPLong-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia20163051044105426837842
   PubMed Web of Science ®Google Scholar
• StegPGBhattDLWilsonPWFOne-year cardiovascular event rates in outpatients with atherothrombosisJAMA200729711119717374814
   PubMed Web of Science ®Google Scholar
• HicksKATchengJEBozkurtB2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trialsJ Am Coll Cardiol201566440346925553722
   PubMed Web of Science ®Google Scholar
• WoodAJJSavageDGAntmanKHImatinib mesylate — a new oral targeted therapyN Engl J Med2002346968369311870247
   PubMed Web of Science ®Google Scholar
• SaglioGKimD-WIssaragrisilSNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med2010362242251225920525993
   PubMed Web of Science ®Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• RixUHantschelODürnbergerGChemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsBlood2007110124055406317720881
   PubMed Web of Science ®Google Scholar
• BuchdungerEZimmermannJMettHInhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimi-dine derivativeCancer Res19965611001048548747
   PubMed Web of Science ®Google Scholar
• KerkeläRGrazetteLYacobiRCardiotoxicity of the cancer therapeutic agent imatinib mesylateNat Med200612890891616862153
   PubMed Web of Science ®Google Scholar
• HochhausALarsonRAGuilhotFLong-term outcomes of imatinib treatment for chronic myeloid leukemiaN Engl J Med20173761091792728273028
   PubMed Web of Science ®Google Scholar
• HatfieldAOwenSPilotPRIn reply to “Cardiotoxicity of the cancer therapeutic agent imatinib mesylate”Nat Med20071311313
   PubMed Web of Science ®Google Scholar
• RibeiroALMarcolinoMSBittencourtHNSAn evaluation of the cardiotoxicity of imatinib mesylateLeuk Res200832121809181418495246
   PubMed Web of Science ®Google Scholar
• EstabraghZRKnightKWatmoughSJA prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinibLeuk Res2011351495121030079
   PubMed Web of Science ®Google Scholar
• AgostinoNMChinchilliVMLynchCJEffect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practiceJ Oncol Pharm Pract201117319720220685771
   PubMedGoogle Scholar
• LassilaMAllenTJCaoZImatinib attenuates diabetes- associated atherosclerosisArterioscler Thromb Vasc Biol200424593594214988091
   PubMed Web of Science ®Google Scholar
• ShahAMCampbellPRochaGQEffect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertensionEur Heart J2015361062363224566799
   PubMed Web of Science ®Google Scholar
• MasudaSNakanoKFunakoshiKImatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteriesJ Atheroscler Thromb201118121043105321996703
   PubMed Web of Science ®Google Scholar
• GilesFJMauroMJHongFRates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysisLeukemia20132761310131523459450
   PubMed Web of Science ®Google Scholar
• DeiningerMO’BrienSGGuilhotFInternational randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinibBlood2009114221119574477
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPWBreitensteinWCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell200574399
   Web of Science ®Google Scholar
• KantarjianHGilesFWunderleLNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med2006354242542255116775235
   PubMed Web of Science ®Google Scholar
• AichbergerKJHerndlhoferSSchernthanerG-HProgressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CMLAm J Hematol201186753353921538470
   PubMed Web of Science ®Google Scholar
• Le CoutrePReaDAbruzzeseESevere peripheral arterial disease during nilotinib therapyJ Natl Cancer Inst2011103171347134821813414
   PubMedGoogle Scholar
• PoredosPJugBThe prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patientsAngiology200758330931517626985
   PubMed Web of Science ®Google Scholar
• DouxfilsJHaguetHMullierFChatelainCGrauxCDognéJ-MAssociation between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survivalJAMA Oncol201625625
   PubMed Web of Science ®Google Scholar
• Chai-AdisaksophaCLamWHillisCMajor arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysisLeuk Lymphoma20165761300131026373533
   PubMed Web of Science ®Google Scholar
• RacilZRazgaFDrapalovaJMechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemiaHaematologica20139810e124e12623716549
   PubMed Web of Science ®Google Scholar
• ReaDMiraultTCluzeauTEarly onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemiaHaematologica20149971197120324658819
   PubMed Web of Science ®Google Scholar
• ShahNPTranCLeeFYChenPNorrisDSawyersCLOverriding imatinib resistance with a novel ABL kinase inhibitorScience2004305568239940115256671
   PubMed Web of Science ®Google Scholar
• LombardoLJLeeFYChenPDiscovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ Med Chem200447276658666115615512
   PubMed Web of Science ®Google Scholar
• CortesJESaglioGKantarjianHMFinal 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trialJ Clin Oncol201634202333234027217448
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHO’BrienSPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol200725253908391417761974
   PubMed Web of Science ®Google Scholar
• MontaniDBergotEGüntherSPulmonary arterial hypertension in patients treated by dasatinibCirculation2012125172128213722451584
   PubMed Web of Science ®Google Scholar
• ShahNPRousselotPSchifferCDasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034Am J Hematol201691986987427192969
   PubMed Web of Science ®Google Scholar
• Remsing RixLLRixUColingeJGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cellsLeukemia200923347748519039322
   PubMed Web of Science ®Google Scholar
• KhouryHJCortesJEKantarjianHMBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood2012119153403341222371878
   PubMed Web of Science ®Google Scholar
• CortesJEJean KhouryHKantarjianHLong-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibAm J Hematol201691660661626971533
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHShahNPPonatinib in refractory Philadelphia chromosome-positive leukemiasN Engl J Med2012367222075208823190221
   PubMed Web of Science ®Google Scholar
• LiptonJHChuahCGuerci-BreslerAPonatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialLancet Oncol201617561262127083332
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHMReaDFinal analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: results with 24 months of follow-upCancer2015121101637164425586015
   PubMed Web of Science ®Google Scholar
• DorerDJKnickerbockerRKBaccaraniMImpact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patientsLeuk Res201648849127505637
   PubMed Web of Science ®Google Scholar
• Poch MartellMSibaiHDeotareULiptonJHPonatinib in the therapy of chronic myeloid leukemiaExpert Rev Hematol201691092393227590270
   PubMed Web of Science ®Google Scholar
• BrecciaMPregnoPSpallarossaPIdentification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionAnn Hematol201796454955827686083
   PubMed Web of Science ®Google Scholar
• HoffmannVSBaccaraniMHasfordJThe EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesLeukemia20152961336134325783795
   PubMed Web of Science ®Google Scholar
• ConroyRMPyöräläKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J20032411987100312788299
   PubMed Web of Science ®Google Scholar
• ReaDMiraultTRaffouxEUsefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemiaLeukemia20152951206120925482133
   PubMed Web of Science ®Google Scholar
• BrecciaMMolicaMZacheoISerraoAAlimenaGApplication of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatmentAnn Hematol201594339339725304102
   PubMed Web of Science ®Google Scholar
• Gerhard-HermanMDGornikHLBarrettC2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelinesJ Am Coll Cardiol20176911e71e12627851992
   PubMed Web of Science ®Google Scholar
• RidkerPMBuringJERifaiNCookNRDevelopment and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk ScoreJAMA2007297661161917299196
   PubMed Web of Science ®Google Scholar
• RidkerPMPaynterNPRifaiNGazianoJMCookNRC-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for menCirculation200811822224351 4p following 225118997194
   PubMed Web of Science ®Google Scholar
• GoffDCLloyd-JonesDMBennettG2013 ACC/AHA guideline on the assessment of cardiovascular riskCirculation201412925 suppl 2S49S7324222018
   PubMed Web of Science ®Google Scholar
• Hippisley-CoxJCouplandCVinogradovaYRobsonJMayMBrindlePDerivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort studyBMJ2007335761113617615182
   PubMed Web of Science ®Google Scholar
• ForceTKolajaKLCardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomesNat Rev Drug Discov201110211112621283106
   PubMed Web of Science ®Google Scholar
• BrownS-ANholaLHerrmannJCardiovascular toxicities of small molecule tyrosine kinase inhibitors: an opportunity for systems-based approachesClin Pharmacol Ther20171011658027806435
   PubMed Web of Science ®Google Scholar
• AndersonTJGrJPearsonGJ2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adultCan J Cardiol201632111263128227712954
   PubMed Web of Science ®Google Scholar
• Ankle Brachial Index CollaborationFowkesFGRMurrayGDAnkle brachial index combined with Framingham risk score to predict cardiovascular events and mortalityJAMA2008300219718612117
   PubMed Web of Science ®Google Scholar
• PolonskyTSMcClellandRLJorgensenNWCoronary artery calcium score and risk classification for coronary heart disease predictionJAMA2010303161610161620424251
   PubMed Web of Science ®Google Scholar
• CapodannoDAngiolilloDJAspirin for primary cardiovascular risk prevention and beyond in diabetes mellitusCirculation2016134201579159427729421
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAKantarjianHRavandiFBleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapyCancer2009115112482249019280591
   PubMed Web of Science ®Google Scholar
• WittelesRMCaliforniaSBiomarkers as predictors of cardiac toxicity from targeted cancer therapiesJ Card Fail201622645946427038641
   PubMed Web of Science ®Google Scholar
• SteegmannJLBaccaraniMBrecciaMEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLeukemia20163081648167127121688
   PubMed Web of Science ®Google Scholar
• ZamoranoJLLancellottiPRodriguez MuñozD2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEur Heart J201637362768280127567406
   PubMed Web of Science ®Google Scholar
• van LeeuwenRWFvan GelderTMathijssenRHJJansmanFGADrug–drug interactions with tyrosine-kinase inhibitors: a clinical perspectiveLancet Oncol2014158e315e32624988935
   PubMed Web of Science ®Google Scholar
• HaoualaAWidmerNDuchosalMAMontemurroMBuclinTDecosterdLADrug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinibBlood20111178e75e8720810928
   PubMed Web of Science ®Google Scholar
• McLaughlinVVShahSJSouzaRHumbertMManagement of pulmonary arterial hypertensionJ Am Coll Cardiol201565181976199725953750
   PubMed Web of Science ®Google Scholar
• ShahNPWallisNFarberHWClinical features of pulmonary arterial hypertension in patients receiving dasatinibAm J Hematol201590111060106426284693
   PubMed Web of Science ®Google Scholar
• HoeperMMBogaardHJCondliffeRDefinitions and diagnosis of pulmonary hypertensionJ Am Coll Cardiol20136225D42D5024355641
   PubMed Web of Science ®Google Scholar
• CortesJEJimenezCAMauroMJGeyerAPinilla-IbarzJSmithBDPleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and managementClin Lymphoma Myeloma Leuk2017172788228082112
   PubMed Web of Science ®Google Scholar
• BrecciaMArboscelloEBellodiAProposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontlineCrit Rev Oncol Hematol201610719019827823647
   PubMed Web of Science ®Google Scholar